Summary

Eligibility
for people ages 1-25 (full criteria)
Location
at UC Davis UCLA UCSF
Dates
study started
completion around
Principal Investigator
by Satiro De Oliveira, MD (ucla)
Headshot of Satiro De Oliveira
Satiro De Oliveira

Description

Summary

Official Title

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Details

Keywords

B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Acute Disease, Dietary Calcium, Leucovorin, Folic Acid, Cytarabine, Dexamethasone, Dexamethasone acetate, Prednisolone, Methylprednisolone Acetate, Methylprednisolone, Methylprednisolone Hemisuccinate, Prednisolone acetate, Hydrocortisone, Hydrocortisone 17-butyrate 21-propionate, Hydrocortisone acetate, Hydrocortisone hemisuccinate, Cyclophosphamide, Doxorubicin, Liposomal doxorubicin, Methotrexate, Vincristine, Daunorubicin, Asparaginase, Mercaptopurine, Pegaspargase, Thioguanine, Inotuzumab Ozogamicin, Prednisolone hemisuccinate, Prednisolone phosphate, BB 1101, Calcium, 2-Aminopurine, Levoleucovorin, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Daunorubicin Hydrochloride, Doxorubicin Hydrochloride, Leucovorin Calcium, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Vincristine Sulfate, HR-FAV B-ALL, MPAL, B-LLY

Eligibility

Locations

Lead Scientist at University of California Health

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Children's Oncology Group
ID
NCT03959085
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 4997 study participants
Last Updated